"The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.
Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infecti"...
Human experience of overdose with OLYSIO is limited. There is no specific antidote for overdose with OLYSIO. In the event of an overdose, the patient's clinical status should be observed and the usual supportive measures employed.
There are no specific contraindications to OLYSIO.
The contraindications to other antiviral drugs administered with OLYSIO for the treatment of CHC infection also apply to OLYSIO combination treatment. Prescribers should consult the complete prescribing information for these drugs for a description of contraindications.
If OLYSIO is administered with Peg-IFN-alfa and RBV, the contraindications for use of Peg-IFN-alfa and RBV also apply to this combination regimen. Refer to the prescribing information for Peg-IFN-alfa and RBV for a list of all contraindications.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/12/2015
Additional Olysio Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.